Author/Authors :
Saki, Najmaldin tarbiat modares university - Faculty of Medical Sciences - Department of Hematology and Blood Banking, تهران, ايران , Abroun, Saeid tarbiat modares university - Faculty of Medical Sciences - Department of Hematology and Blood Banking, تهران, ايران , Soleimani, Masoud tarbiat modares university - Faculty of Medical Sciences - Department of Hematology and Blood Banking, تهران, ايران , Hajizamani, Saeideh ahvaz jundishapur university of medical sciences - Health research institute, Research Center of Thalassemia Hemoglobinopathy, اهواز, ايران , Shahjahani, Mohammad tarbiat modares university - Faculty of Medical Sciences - Department of Hematology and Blood Banking, تهران, ايران , Kast, Richard E. IIAIGC Headquarters, USA , Mortazavi, Yousef zanjan university of medical sciences - Faculty of Medicine - Department of Pathology, ايران
Abstract :
MicroRNAs are 19-22 nucleotide RNAs involved in such important processes as development, proliferation, differentiation and apoptosis.Different miRNAs are uniquely expressed in lymphoid T cells, and play a role indevelopment and differentiation of various subtypes by targeting their target genes. Recent studies have shown that aberrant miRNA expression may be involved in T cell leukemogenesis and lymphogenesis, and may function as tumor suppressor (such as miR-451, miR-31, miR-150, and miR-29a) or oncogene (e.g. miR-222, miR-223, miR-17-92, miR-155). MiRNAs can be used as new biomarkers for prognosis and diagnosis or as an index of disease severity in T-cell leukemia and lymphoma. This article presents a review of studies in recent years on the role of miRNAs in T-cell development and their aberrant expression in pathogenesis of T-cell leukemia and lymphoma.Characterizing miRNAs can help recognize their role as new important molecules with prognostic and therapeutic applications.
Keywords :
MicroRNA , Leukemia , Lymphoma , Tumor Suppressor , Oncogene
